Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2019-10-30 Capital/Financing Update
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Section 708A Notice 1 page 107.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX Market Announcement regarding a Section 708A(5)(e) Notification under the Corporations Act 2001. It informs about the issue of ordinary shares and the associated exemption from disclosure requirements. The content is a regulatory notice about a capital raising event without detailed financial statements or analysis. The document length is short (2092 characters) and it serves as an announcement rather than a full report. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2019-10-30 English
Change in substantial holding 5 pages 237.0KB
Regulatory Filings
2019-10-29 English
Appendix 3B 13 pages 221.1KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to a new issue of securities, specifically unlisted options, by Genetic Technologies Limited. It includes detailed information about the class of securities issued, number of securities, exercise price, issue price, purpose of the issue, security holder approvals, and calculation of placement capacity under ASX rules 7.1 and 7.1A. The document is a formal notification to the ASX (Australian Securities Exchange) about the issuance and quotation of additional securities. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital raising and securities issuance. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2019-10-29 English
Becoming a substantial holder 3 pages 87.0KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under the Corporations Act 2001. It details the substantial shareholding of Peter Irwin Rubinstein and associated entities in Genetic Technologies Limited, including voting power, relevant interests, registered holders, consideration paid, and associates. This type of filing is a notification of a major shareholding change, specifically the initial substantial holder notice. It is not an annual report, earnings release, or any other financial report. It fits the definition of Major Shareholding Notification (MRQ). The document length is 8694 characters, which is substantive and contains detailed shareholding information, not just an announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2019-10-29 English
Becoming a substantial holder 3 pages 84.7KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under the Corporations Act 2001. It details the substantial shareholding of Jerzy Muchnicki and associated entities in Genetic Technologies Limited, including voting power, relevant interests, registered holders, consideration paid, and associates. This type of filing is a notification of a major shareholding change, specifically the initial substantial holder notice. It is not an annual report, earnings release, or any other financial or management report. The document fits the definition of a Major Shareholding Notification (MRQ) as it reports changes in significant share ownership levels crossing thresholds.
2019-10-29 English
Completed Capital Raise and NASDAQ Compliance 2 pages 163.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX market announcement regarding Genetic Technologies Limited's successful capital raise and compliance with Nasdaq listing requirements. It details the completion of a $4.5 million rights offering, the company's regained compliance with Nasdaq's minimum stockholders' equity rule, and ongoing monitoring by Nasdaq. The document is relatively short (3947 characters) and serves as an update on financing and regulatory compliance rather than a full financial report or detailed earnings release. It does not contain comprehensive financial statements or detailed management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2019-10-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.